Endometrial cancer

42 trials 26 recruiting MedDRA PT
42 Registered trials
26 Recruiting
31 Unique sponsors
39 Unique IMPs
37 Commercial trials
Drug classes (ATC)
— ATC code not specified 31
L Oncology (ATC L) 11
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 21 substances
Kinase inhibitor 3 substances
Monoclonal antibody (immune) 3 substances
Antibody-drug conjugate (ADC) 3 substances
Monoclonal antibody 2 substances
Antimetabolite 1 substance
Checkpoint inhibitor (PD-1) 1 substance
PARP inhibitor 1 substance
Anthracycline 1 substance
Taxane 1 substance
Monoclonal antibody (rat) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 8 Phase II: 13 Phase I/II: 3 Phase I: 10 Phase I (Other): 1 Phase I (First in Human): 7

Filter these 42 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 42 trials

Phase III

8 trials
  • AstraZeneca AB Commercial
    RILVEGOSTOMIG; TRASTUZUMAB DERUXTECAN
    2023-508056-19-00 13 countries 2025 n=219
    Recruiting
  • AstraZeneca AB Commercial
    OLAPARIB
    2024-512982-15-00 12 countries 2021 n=94
    Recruiting
  • BioNTech SE Commercial
    DB-1303; DOXORUBICIN HYDROCHLORIDE; PACLITAXEL
    2023-507525-42-00 15 countries 2025 n=222
    Recruiting
  • Genmab A/S Commercial
    RINATABART SESUTECAN
    2024-519818-31-01 11 countries n=226
    Pending
  • Karyopharm Therapeutics Inc. Commercial
    IMP not specified
    2024-513167-68-00 6 countries 2017 n=70
    Ended
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB
    2025-524160-38-00 10 countries 2026 n=37
    Recruiting
  • Arcagy Gineco Academic
    IMP not specified
    2023-510097-14-00 4 countries 2022 n=217
    Ended
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513079-42-00 1 country 2015 n=262
    Ended

Phase II

13 trials
  • Acrivon Therapeutics Inc. Commercial
    GEMCITABINE; PREXASERTIB LACTATE MONOHYDRATE
    2025-524542-10-00 4 countries 2026 n=72
    Recruiting
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Corcept Therapeutics Inc. Commercial
    RELACORILANT
    2024-517432-21-00 6 countries 2025 n=177 Orphan
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2024-513307-13-00 5 countries 2025 n=73
    Ended
  • F. Hoffmann-La Roche AG Commercial
    GIREDESTRANT
    2023-504091-23-00 2 countries 2023 n=9
    Ended
  • Genmab A/S Commercial
    GEN1046; PEMBROLIZUMAB
    2022-502453-33-00 5 countries 2024 n=43
    Ended
  • Incyte Corp. Commercial
    HUMAN IGG1K MONOCLONAL ANTIBODY AGAINST TIM-3; PEMIGATINIB; RETIFANLIMAB; TUPARSTOBART
    2022-502600-79-00 4 countries 2021 n=88
    Ended
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN
    2023-504445-31-00 4 countries 2024 n=28
    Recruiting
  • Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial
    PEMBROLIZUMAB; SKB264
    2022-502654-14-00 4 countries 2023 n=101
    Recruiting
  • Grupo Espanol De Investigacion En Cancer De Ovario Academic
    DOSTARLIMAB
    2024-512021-81-00 1 country 2025 n=25
    Recruiting
  • Universitair Medisch Centrum Groningen Academic
    PEMBROLIZUMAB
    2024-516736-10-00 1 country 2023 n=12
    Recruiting
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-517363-24-00 1 country 2024 n=100
    Recruiting

Phase I/II

3 trials
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Eisai Limited Commercial
    FARLETUZUMAB ECTERIBULIN; LENVATINIB
    2023-506868-14-00 2 countries 2023 n=90
    Ended
  • Eisai Limited Commercial
    (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE; DOXORUBICIN HYDROCHLORIDE; LENVATINIB; PACLITAXEL
    2023-510275-64-00 4 countries 2023 n=83
    Recruiting

Phase I

10 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2025-524334-26-01 1 country 2026 n=15
    Recruiting
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-511744-27-00 2 countries 2022 n=240
    Ended
  • Ikena Oncology Inc. Commercial
    IMP not specified
    2022-502622-40-00 4 countries n=31
    Ended
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
  • Seagen Inc. Commercial
    SGN-ALPV
    2022-500094-14-00 3 countries 2022 n=82
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Zymeworks Inc. Commercial
    IMP not specified
    2024-512299-37-00 1 country 2026 n=18
    Recruiting

Phase I (Other)

1 trial
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended

Phase I (First in Human)

7 trials
  • BioNTech SE Commercial
    BNT142
    2024-512639-58-00 3 countries 2022 n=119
    Ended
  • BioNTech SE Commercial
    BNT329
    2025-522613-26-00 2 countries 2026 n=90
    Recruiting
  • Crescent Biopharma Inc. Commercial
    CR-001
    2025-523590-42-00 1 country n=44
    Pending
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Pmv Pharmaceuticals Inc. Commercial
    PC14586
    2023-504251-27-00 4 countries 2024 n=105
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; SARILUMAB; UBAMATAMAB
    2024-510783-23-00 5 countries 2020 n=237
    Recruiting
  • Scorpion Therapeutics Inc. Commercial
    IMP not specified
    2023-504807-94-00 7 countries 2023 n=178
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 4 Phase I, Phase II 2
Daiichi Sankyo Inc. Commercial 3 Phase II, Phase I (First in Human), Phase I/II 2
BioNTech SE Commercial 3 Phase III, Phase I (First in Human) 2
BeOne Medicines AG Commercial 2 Phase I 2
Genmab A/S Commercial 2 Phase II, Phase III 0
AstraZeneca AB Commercial 2 Phase III 2
Eisai Limited Commercial 2 Phase I/II 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I 1
Cullinan Therapeutics Inc. Commercial 1 Phase I 0
Ikena Oncology Inc. Commercial 1 Phase I 0
Immunocore Limited Commercial 1 Phase I 1
Zymeworks Inc. Commercial 1 Phase I 1
Exelixis Inc. Commercial 1 Phase I (Other) 0
Acrivon Therapeutics Inc. Commercial 1 Phase II 1
Bayer Consumer Care AG Commercial 1 Phase II 1
Corcept Therapeutics Inc. Commercial 1 Phase II 1
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 0
Jazz Pharmaceuticals Ireland Limited Commercial 1 Phase II 1
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial 1 Phase II 1
New trials by year
2020
1
2021
2
2022
5
2023
7
2024
7
2025
8
2026
7
← All indication landscapes